| Ytd | -19.06% | |
| 1y | -43.57% |
| Open | 0.82 | Prev Close | 0.80 | Low | 0.79 | High | 0.83 | Mkt Cap | 5.64M |
| Vol | 40.06K | Avg Vol | 968.44K | EPS | -1.27 | P/E | N/A | Forward P/E | -1.15 |
| Beta | 0.57 | Short Ratio | 0.25 | Inst. Own | 5.31% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 0.85 | 200-d Avg | 0.98 | 1yr Est | 4.50 |
HOTH News
Hoth Therapeutics stock surged after announcing its Rocket One rebrand and new AI chip technology fo
Company Adopts Space-Focused Identity, New Ticker "RKTO," and Exclusive License of AI Chip Architect
Allowed Claims Cover Composition-of-Matter and Methods Targeting MS4A6A Pre-mRNA Splicing to Reduce
Company Targets Power Demands of AI Data Centers Through Patented Nanomagnetic Semiconductor and Spi
Regulatory Clearance in Spain Advances Randomized, Placebo-Controlled Study; Patients Show Meaningf
Statistically Significant Reduction in Srebf1 (Fat Production) and Increased Pparα (Fat Metabolism)
Bloom Energy (BE) rose in pre-market trading as it announces expanded partnership with Oracle (ORCL)
Statistically Significant Reduction in Srebf1 (Fat Production) and Increased Pparα (Fat Metabolism)
NEW YORK, April 2, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage bio
NEW YORK, April 1, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage bio
Over 65% of Patients Reported Reduced Pain and Itching; Zero Disruptions to EGFR Cancer Therapy with
Technology Selectively Shuts Down Cancer Reproducing Cells Patent Covers Splice-Switching Oligonucle
NEW YORK, March 26, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage bi
PK studies of topical HT-001 reveal limited systemic absorption and ~99% reduced systemic levels as
HT-VA restores cholesterol to control-diet levels and maintains lower triglycerides compared with se
AI Integration Supports IND Preparation & Phase 1 Progression for Rare KIT-Driven Cancers NEW YORK,
CLEER-001 Phase 2a Expansion Signals Growing Momentum Behind First-in-Class Therapy for Cancer Patie
In a head-to-head preclinical comparison, HT-VA co-developed with the United States Veterans Adminis
Hoth Therapeutics Inc. (NASDAQ: HOTH) on Tuesday revealed preclinical data from its study on glial c
NEW YORK, Feb. 5, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biop
Primary endpoint ARIGA improved by ~50% from baseline by Week 6, with all evaluable patients reachin
On Thursday, 369 companies hit new 52-week lows.
On Monday, 369 companies set new 52-week lows.
U.S. stocks traded mixed toward the end of trading, with Dow Jones dropping over 100 points on Tuesd
U.S. stocks traded mixed midway through trading, with Nasdaq Composite turning higher on Tuesday. T
On Wednesday, 345 companies set new 52-week lows.
Tuesday's session saw 286 companies set new 52-week lows.
On Monday, 198 companies hit new 52-week lows.